A cross-sectional, multicentre, retrospective study assessing therapy choice, treatment patterns and outcomes in patietnts with unresectable advanced or metastatic BRAFV600E/K-positive malignant cutaneous Melanoma
Latest Information Update: 15 Jul 2020
At a glance
- Drugs Cobimetinib (Primary) ; Dabrafenib (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary) ; Talimogene laherparepvec (Primary) ; Trametinib (Primary) ; Vemurafenib (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 15 Jul 2020 New trial record
- 08 Jul 2020 Results published in the Advances in Therapy